Yellow Cake

Phase A — Understand the business

Company Overview

What it is, in plain terms. Yellow Cake plc is a closed-end physical-uranium holding vehicle: it raises equity, uses the cash to buy triuranium octoxide (U3O8, "yellowcake"), stores it in licensed converter facilities, and holds it — indefinitely. There is no mining, no conversion, no enrichment, no trading desk running a book. One share ≈ a fractional claim on a pile of uranium plus a small cash balance. The entire investment case reduces to: (a) the uranium price, (b) GBP/USD, (c) the discount/premium the market applies to NAV, and (d) fees.

The numbers that define it (as at 31 March 2026, its fiscal year-end):

• Physical holding: 23.11 million lb U3O8, up from 21.68 M lb three months earlier; pro-forma ~24.27 M lb after purchases in delivery.
• Uranium portfolio value: US$1.94 billion (+9.7% in the quarter).
• NAV per share: 633p, +5.0% q/q (from 603p at 31 Dec 2025), +25% y/y (from 505p).
• Shares outstanding: 252,659,183; market cap £1.53bn ($1.9bn).
• Share price: ~526.5–541p (8 Jul 2026).
• Dividend: none — this is a pure NAV-accretion vehicle; all return is price/NAV. [structural — no distribution policy]

Domicile & listing. Jersey-incorporated, London-listed on AIM (LON:YCA), secondary OTC in the US (YLLXF). Founded and brought to market by Bacchus Capital Advisers (still Financial Adviser); IPO July 2018.

"Customers/suppliers/competitors" (re-pointed — a holding vehicle has none of the usual kind):

• Supplier of uranium: primarily JSC Kazatomprom (the world's largest producer) under a bilateral Framework Agreement (Lens 2), plus opportunistic spot-market purchases.
• Service providers: 308 Services Ltd (uranium management/administration, storage negotiation — the outsourced "manager", see Lens 9/fees); Cameco and Orano as storage converters (Lens 2).
• "Customers": none — Yellow Cake does not sell into a market; its shareholders are its only counterparties. It has occasionally executed small opportunistic sales/loans in the past but the mandate is buy-and-hold.
• Competitors for investor capital: Sprott Physical Uranium Trust (SPUT) — the larger, North-American physical twin; uranium-miner equities (Cameco, Kazatomprom, NexGen); and holding spot directly (not practical for most investors).

Contract structure / key terms. The one contract that matters is the Kazatomprom Framework Agreement — an annual option (not obligation) to buy up to US$100m of U3O8 per year at prevailing spot, running from the 2018 IPO through 2027 (Lens 2). No take-or-pay, no recurring revenue — the "contract" is an embedded call option on cheap sourcing.

---

Supply Chain

Map: producer → converter/storage → Yellow Cake (title holder) → (ultimately) a utility, someday. Every named stakeholder:

Kazatomprom (Kazakhstan, ISR mines) ──► [primary supply, via Framework Agreement option]
Spot market (traders/producers) ──► [opportunistic top-ups]
 │
 ▼
 Yellow Cake plc (holds title to U3O8; does NOT take physical custody itself)
 │
 ▼
Storage / conversion counterparties:
 • Cameco — Port Hope / Blind River, Ontario, Canada
 • Orano Cycle — Malvési / Tricastin, France
 │
 ▼
 (No onward sale in the base case — buy-and-hold. End demand = the ~440 global
 reactors + AI-datacenter nuclear buyers that set the uranium price YCA marks against.)

Chokepoints & single-source dependencies:

1. Kazatomprom concentration on the buy-side. The differentiating supply channel is a single counterparty in Kazakhstan — a jurisdiction with routing exposure (historically shipped via the Trans-Caspian / non-Russian routes after 2022). If Kazatomprom under-produces (it cut 2026 output ~10%, see Lens 8/12) or the option lapses (2027), the cheap-sourcing edge evaporates.
2. Two converters hold the physical. Custody sits with Cameco (Canada) and Orano (France) — both blue-chip Western converters, which is a strength (no Russian storage, unlike some peers historically). But it concentrates custodial/counterparty risk in two names and two jurisdictions.
3. The uranium itself is the choke point for the whole thesis. Yellow Cake is a leaf node: it consumes uranium and produces nothing. Its "supply chain" resilience is entirely borrowed from the physical U3O8 market's tightness (Lens 12).

Names or it didn't happen: Kazatomprom (supply), Bacchus Capital (adviser/placing agent), 308 Services (manager), Cameco + Orano (converters/storage). That is the entire chain — the simplicity is the point.

---

Competitive Advantages (moats)

For a commodity-holding shell, "moat" means structural cost/access advantages that let it accrete NAV per share faster than a rival vehicle or than holding spot directly. Four real ones, one soft:

1. The Kazatomprom Framework Agreement (the genuine differentiator). A pre-negotiated annual right to buy $100m/yr at spot from the lowest-cost producer on earth — secured in 2018 when nobody wanted uranium. In a tight market this lets YCA add pounds without moving the thin spot tape against itself, whereas a fund buying only on the spot market pushes price up as it buys. But it is a wasting asset — it runs out in 2027. This is the single most important moat and the single biggest structural clock.
2. Cost structure (see fee detail, Lens 10). Holding fee ≈ $275k fixed + 0.275% of U3O8 value above $100m; total ongoing cost ~0.3–0.4% of NAV/yr. Very low for a physical vehicle — comparable to or below SPUT. Low frictional drag = tighter NAV tracking = the moat vs. an expensive actively-managed fund.
3. Western-only custody. All-in Cameco/Orano storage (no Russian custody) is a real quality/liquidity advantage post-2022 for Western institutional buyers with sanctions constraints.
4. Scale & liquidity vs. a retail investor buying spot. ~$1.9bn cap, daily LSE liquidity, and it can issue at a premium / buy back at a discount — a self-correcting NAV mechanism most investors can't replicate.
5. (Soft) Brand as "the uranium proxy." First-mover AIM name; recognised shorthand for "long uranium." Real for flows, but not durable — SPUT is bigger and equally recognised.

Bargaining power. Essentially none over uranium price — YCA is a price-taker in a producer-controlled market (Kazatomprom + Cameco discipline the price). Its only leverage is the timing of exercising its option and issuing/buying-back stock. Against its service providers (308 Services, converters) it has ordinary commercial leverage on a small fee base. This is a moat over tracking efficiency, not over the underlying commodity. Anyone confusing the two is mispricing the risk.

---

Segments — re-pointed to holdings composition (no product/geo P&L exists)

There are no revenue segments. The only meaningful decomposition is NAV by component and holdings by source/location:

vs total NAV ≈ 252.66M sh × £6.33 = £1.599bn ≈ $1.94bn at GBP/USD ≈ 1.21 → uranium ≈ ~97–100% of NAV, small cash offset by accrued fees/liabilities]

Holdings by sourcing channel: the bulk accreted via (a) the 2018 IPO seed purchase, (b) the 2021 raises (8.35 M lb added), and (c) successive annual Kazatomprom option exercises + spot top-ups. Storage split: across Cameco (Canada) and Orano (France) — the company does not publish a fixed ratio; both are material.

Trend: holdings have compounded upward every year the vehicle could issue at/near NAV — 8.35 M lb added in 2021; steady annual option exercises since; 21.68 → 23.11 M lb in Q4-FY26 alone. The "segment trend" that matters is lb U3O8 per share — the only figure that makes a passive holding vehicle better over time (NAV/share also moves with price, but pounds/share is the accretion scorecard). Recent issuance has been NAV-accretive (issued at premium) and recent buybacks NAV-accretive (bought at discount) — both add pounds/share.

---

Phase B — Measure performance

"Earnings result" — re-pointed to the latest NAV/operating update (the quarterly NAV print is the earnings for a holding vehicle)

The Q4-FY26 update (quarter to 31 March 2026) is the relevant "print". There is no revenue/EPS; the scoreable outputs are NAV/share, the uranium mark, FX, and holdings.

• NAV/share 633p, +5.0% q/q, +25% y/y. Driver decomposition: uranium price up + GBP weaker vs USD (YCA's assets are USD, its shares quoted in GBP, so a falling pound mechanically lifts the pence NAV).
• Uranium portfolio +9.7% q/q to $1.94bn — the mark, driven by U3O8 rising into the low-$80s/lb through Q1 2026.
• Holdings +6.6% q/q (21.68 → 23.11 M lb) via Kazatomprom deliveries + selective spot buys.
• Guidance/outlook: none in the earnings sense. Forward "guidance" = the funded 2026 Kazatomprom option (~1.16–1.33 M lb at $86.15/lb) plus stated intent to keep accreting.
• Balance-sheet flags: clean by construction — no debt (equity-funded), the "inventory" is the entire asset and is marked to spot, no receivables. The only "cash burnCash burnHow much more cash goes out than comes in, per period. The clock on a company with no profits." is fees + storage (~$8–9m/yr, Lens 10). Solvency risk ≈ nil; the risk is asset price, not balance sheet.
• Market reaction / what's priced in: despite the +25% y/y NAV, the shares de-rated to a discount through H1 CY2026 — by June wide enough (≥10%) to trigger the first-ever buyback (Lens 8/9). Translation: the market stopped paying up for uranium exposure and started demanding a discount — the single most important behavioural fact in this dossier.

Unusual vs. its own history: the buyback itself is the anomaly. For seven years Yellow Cake only ever issued stock (at premiums). Switching to repurchasing is a regime change — it signals the board judges the discount too wide to issue into, and would rather shrink the share count than grow the pile. Bullish for per-share value, bearish as a read on near-term demand for the equity.

---

"Earnings calls" — re-pointed to management commentary & sentiment trend

Yellow Cake runs quarterly operating updates + interims/annuals + CEO media (Crux Investor, AJ Bell, sector press) rather than sell-side earnings calls. Sentiment trend across the last ~4 communications:

• Consistent, un-hedged structural bullishness on uranium — CEO Andre Liebenberg frames every update around supply deficit, utility under-contracting, and the term-price/spot divergence. Recurring phrases: "attractive entry point," "discount to underlying value," "long-term exposure to the uranium price," "differentiated by the Kazatomprom agreement."
• The tone shift in 2026: from "issue and grow" (2021–2024, when the shares carried a premium) to "the market is undervaluing us — so we'll buy our own stock" (June 2026). The board explicitly called the discount an "attractive opportunity … to increase shareholders' exposure … at a discount to underlying value." Management stopped talking about placings and started talking about the discount — a clean sentiment inflection.
• What they stopped saying: the 2021–24 growth-by-issuance narrative. What they started saying: capital discipline / per-share accretion via buyback.

This lens is low-information for a passive vehicle (there's no operating execution to assess) — management's "sentiment" is really a uranium-market view plus a capital-allocation stance, both covered better in Lenses 9 and 12.

---

Comps

The honest comp set has two tiers: (1) the direct structural twin (another physical-only holder — SPUT), which is the only true apples-to-apples; and (2) uranium equities (producers/developers), which are not comparable on multiples (they have opex, reserves, leverage, and optionality YCA lacks) but frame the opportunity set for a "long uranium" dollar.

Tier 1 — the real comp (physical holders):

SPUT is ~3.3× the pounds and ~3.3× the cap — the deeper, more liquid vehicle, with an at-the-market issuance engine that, when it trades at a premium, can buy spot aggressively and tighten the whole market (the 2021 "SPUT effect"). YCA's edge vs SPUT is the Kazatomprom option (off-market sourcing) and, right now, a wider discount (cheaper entry to the same asset).

Tier 2 — uranium equities (context, NOT valuation comps):

---

Stock-Price Catalysts (moves >5%, ~5-year history)

YCA is beta to uranium + discount sentiment — its >5% moves cluster around uranium-price regime shifts and flow events, essentially never around company-specific "execution":

• Mar 2020 → 152p (COVID trough).
• 2021 SPUT-driven rally: ~247p (Aug) → ~345p (Sep 2021). Sprott's ATM launched, bought ~6 M lb over summer 2021 (SPUT to ~24 M lb), tightening thin spot — the archetypal "financial demand tightens the tape" event. YCA raised $375.1m across two placings and added 8.35 M lb into the move.
• Feb 2024: uranium spikes to a 16-year high ~$107/lb; YCA re-rates hard; July 2024 ~539.5p (+33% y/y).
• 2024–25 consolidation: uranium pulls back from $107 toward the mid-$80s; YCA trades a wide band. Trailing-year range ~462p–750p.
• Q1 2026: uranium firms into low-$80s, term price to ~$91.50 (16-yr high); NAV +25% y/y; shares briefly trade above NAV, then de-rate.
• 15 Jun 2026: first-ever buyback ($10m, later "substantially increased"); 376,000 sh bought 15–19 Jun at 562p ($2.8m). Discount-driven, not price-driven.

Pattern / what the market actually reacts to: (1) the uranium spot price (the dominant driver), (2) financial-demand/flow shocks (SPUT ATM, its own placings), and (3) the discount/premium regime — not earnings, not guidance, not management. There is no idiosyncratic alpha here; YCA is a transmission line for the uranium price, and the only company-specific lever is the discount (which the buyback now actively targets).

---

Phase C — Judge people & books

Management & capital allocation

• CEO — Andre Liebenberg. 25+ yrs resources: senior roles at BHP Billiton, then CFO of QKR Corporation, before founding-CEO of Yellow Cake at the 2018 IPO. Resource-finance pedigree fits a capital-allocation vehicle.
• Sponsor — Bacchus Capital Advisers. Originated and IPO'd the vehicle in 2018 (when uranium was ~$20/lb and deeply out of favour — a genuinely contrarian, well-timed launch) and remains Financial Adviser/placing agent.
• Manager — 308 Services Ltd runs uranium administration, storage negotiation and custody oversight under the 2018 services agreement (fees in Lens 10). The operating footprint is deliberately tiny — this is an outsourced, low-headcount structure.

Track record — quantified & genuinely good for the mandate:

1. Timing. Launched 2018 near the cycle bottom; NAV/share compounded from IPO (issue price 200p) to 633p by Mar 2026 — the vehicle did its job through a full uranium up-cycle.
2. Disciplined, NAV-accretive capital allocation — the single most important thing a holding vehicle can get right, and YCA gets it textbook-right:

• Issues ONLY at/around a premium to NAV (2021 $375m; 2025–26 raises to fund Kazatomprom options) → new shares add pounds/share.
• Buys back ONLY at a ≥10% discount to pro-forma NAV (June 2026, first ever) → repurchased shares add pounds/share.
• Fully exercises the Kazatomprom option in tight markets (cheap sourcing) and tops up on spot opportunistically. This is the closed-end-vehicle discipline most trusts fail — YCA's board has been on the right side of its own discount both directions.

1. Skin in the game / red flags: insider ownership not sourced here (n/a); no related-party or aggressive-accounting flags surfaced (Lens 10). The one governance nuance: the external-manager structure (308 Services) means fees are paid to a related service entity rather than in-house — standard for the format, but worth watching that the fee scales with the pile not with per-share performance.

Archetype: professional capital allocator running a passive vehicle — exactly the right archetype for this stage. The job is not to be visionary; it's to accrete pounds/share and mind the discount. On that scorecard, management has executed well.

---

Forensic Red Flags + fees + Regulatory

Accounting risk — low by construction, but not zero:

• Asset valuation (the whole balance sheet). NAV ≈ 97% one asset (U3O8) marked to the spot price. Mark integrity depends on which price index and date is used — spot is thin and can gap; a stale or favourable mark would flatter NAV. No revenue-recognition, lease, or receivables complexity because there's no operating business. Watch: the spot reference used for the NAV mark.
• Fee drag (the real "expense" line) — the numbers, from the 2018 services agreement with 308 Services:
• Holding Fee = $275,000 fixed/yr + 0.275%/yr of the value of U3O8 holdings above $100m. On $1.94bn: 0.275% × ($1.94bn − $0.1bn) = ~$5.06m + $0.275m ≈ ~$5.3m/yr.
• Annual Storage Incentive Fee = 33% of the difference between a Target Storage Cost ($0.12/lb/yr initially) × lb held, and actual converter storage fees paid — i.e. 308 keeps a third of any storage saving vs target (an alignment incentive).
• Plus physical storage costs at Cameco/Orano (~$0.12/lb/yr order-of-magnitude → ~$2.8m/yr on 23 M lb).
• All-in ongoing cost ≈ ~0.3–0.4% of NAV/yr. Cheap for a physical vehicle, roughly in line with SPUT (~0.35% + expenses). But note it's a % of gross assets, so the absolute fee grows with the pile, and it is paid to a related manager — the mild structural tension to monitor.
• Cash-flow vs earnings divergence: N/A in the usual sense — "earnings" = NAV moves = unrealised mark changes; there is little cash flow at all (no sales). The only cash out is fees/storage. No SBC flattering non-GAAP. No goodwill/intangibles.

Where a skeptic would dig: (1) the spot-price mark used for NAV; (2) whether the storage-incentive fee ever incentivises the manager toward its own interest over shareholders'; (3) counterparty/custody documentation at Cameco/Orano (title vs. commingling). None of these are red flags on the evidence — they are the only places a passive vehicle can hide risk.

Regulatory findings (required sub-section):

• SEC (EDGAR LR/AAER): none possible — Yellow Cake has no CIK; it is not an SEC filer. regulatory/regulatory-findings.md confirms total_sec_findings: 0 and notes the no-CIK limitation.
• Non-SEC web search ("Yellow Cake" (FTC OR DOJ OR FDA OR CFPB OR "consent decree" OR settlement OR fine OR penalty) enforcement): no material enforcement action surfaced. The name-collision with the generic "yellowcake" term produces noise but no regulator action against Yellow Cake plc.
• UK/AIM disclosure regime: as an AIM company it is subject to the AIM Rules + UK MAR (via its Nomad/Bacchus). No sanctions/censure surfaced.
• Item 3 / Legal Proceedings equivalent: no 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. exists; UK annual report legal-proceedings disclosure not on the shelf — n/a (would be verified from the 31 Mar 2026 Annual Report if pulling primary UK filings).
• Verdict: No material regulatory or legal findings — verified via SEC EDGAR EFTS (nil, no CIK) and web search as of 2026-07-10; UK Annual Report legal note not independently pulled.

---

Phase D — Project & stress-test

Forward Projection — re-pointed to forward NAV/share (no EPS exists)

There is no EPS to model. The scoreable output is forward NAV per share, which is a near-deterministic function of (uranium price × lb held) ± FX ± discount-normalisation − fees. Building it bottom-up from the 31 Mar 2026 anchor (NAV 633p; ~23.1 M lb; ~$84/lb spot mark; GBP/USD ≈ 1.21; 252.7 M sh):

Sensitivity (the only model that matters) — NAV/share vs uranium price, holding lb & FX ≈ constant:

• Uranium is ~97% of NAV, so NAV/share moves ~1:1 with the U3O8 price (in USD), then translated at GBP/USD.
• Rule of thumb: every +$10/lb ≈ +~$0.23bn NAV ≈ +~11–12% to NAV/share (23.1 M lb × $10 / ~$1.94bn). A weaker pound adds on top; a stronger pound subtracts.

; FX assumption flat; discount is a behavioural variable, not a fundamental one.]

Two independent return sources: (1) the uranium price (the beta you're buying), and (2) discount closure — from ~−16% today toward ~−5%/par is a ~+13% standalone re-rating even if uranium goes nowhere, and the buyback is now actively pushing on it. The base case is roughly "uranium flat, discount half-closes" → high-single/low-double-digit upside; the bull case needs uranium to converge to its own term price.

No our model create — per the --watchlist rule (breadth mode logs no Brier forecast) and the task's explicit instruction. If promoted to a call, the tracked forecast would be a binary on discount closure (e.g., "YCA price/NAV ≥ 0.92 within 12 months"), not an EPS line.

---

Bull vs Bear

Bull case. You are buying ~23 M lb of physical uranium at an implied ~$70/lb (Lens 11) — ~18% below the ~$85 spot and ~23% below the ~$91.50 term price — in a market with a structural, multi-year supply deficit. The demand side is the strongest it's been in a generation: AI-datacenter nuclear demand (Meta/Amazon/Microsoft capacity deals), reactor life-extensions and restarts, the Russian-enriched-uranium import ban (full effect 2028) forcing Western fuel-cycle rebuild (DOE's $900m HALEU awards to Centrus/General Matter; Orano LEU expansion), and utilities pivoting from spot to long-term contracting into a market where production must rise ~2.5× by 2030–33 to meet requirements. Kazatomprom (the swing producer) is cutting 2026 output ~10% — "nuclear OPEC" discipline supporting price. On top of the commodity, YCA offers two free options: the discount closing (buyback active) and the Kazatomprom sourcing edge (through 2027). Cleanly-run, no debt, no operational blow-up risk.

Bear case (the risks that permanently impair or cap it):

1. It's pure beta with a lid. YCA cannot outperform uranium — it is uranium, minus fees, minus (potentially) a persistent discount. Miners like Cameco give you operational leverage and dividends; YCA gives you the commodity and a management fee. If you're bullish uranium, a producer may simply be the better vehicle.
2. The discount can be structural, not transient. Closed-end vehicles trade at persistent discounts for years (see the entire UK investment-trust sector). A ~15% discount is not guaranteed to close — the buyback is small ($10m on a $1.9bn cap) and can only lean against it. The bull's "free re-rating" may never arrive.
3. Uranium price is a speculative, thin, policy-driven market. It ran to $107 in Feb 2024 and gave most of it back. A demand disappointment (AI-datacenter nuclear slips, reactor delays), a Kazatomprom production restoration, or a SPUT-style forced/unwind of financial demand could take spot back to the $60s — directly re-pricing NAV down ~15–20%, and a widening discount would compound it.
4. The Kazatomprom edge expires in 2027. The single genuine moat is a wasting asset. Post-2027, YCA is just a physical holder competing with the larger, more liquid SPUT.

Pre-mortem (it's Jan 2028, thesis broke — what happened?): Uranium faded from ~$85 to the mid-$60s as AI-nuclear demand proved slower/lumpier than the 2025–26 hype and Kazatomprom restored cut barrels; the Framework Agreement lapsed at end-2027 with no renewal; the discount widened to ~25% as generalist holders exited a "boring" single-commodity shell; NAV fell ~20% and the price fell ~30%. The buyback was a rounding error against the outflow.

Are multiples too high? There is no multiple — but paying near or above NAV (as it briefly did in Q1 2026) is the expensive state; paying a ~15% discount (today) is the cheap state. Today's entry is not rich.

Contrarian view (what the market refuses to see): the market treats the ~15% discount as a warning sign and is selling, when for a buy-and-hold physical holder the discount is the whole edge — you accrete pounds/share via the buyback and you own the commodity below spot. The market is also under-weighting that the term price ($91.50) already sits well above spot ($85) — i.e., the smart contracted money is paying up for future pounds while the YCA tape prices YCA's existing pounds at ~$70. That gap is the mispricing.

---

Devil's Advocate (short-seller)

I am dismantling the bull case.

• The "moat" is rented and expiring. Strip the Kazatomprom option (gone 2027) and Yellow Cake is a strictly inferior SPUT: one-third the pounds, one-third the liquidity, no ATM engine, and on a junior exchange (AIM). Why own the small copy when the large original exists? Post-2027 the only differentiator is which discount is wider on the day.
• Revenue concentration? There is no revenue — there is asset concentration, and it's 100%. Every eventuality flows through a single, thin, manipulable spot price. This is the opposite of a diversified business — it's a leveraged (via discount) single-variable bet dressed up as an "investment company."
• The discount is telling you something. Sophisticated holders are demanding ~15% less than NAV to own this — that's the market pricing (a) fee drag in perpetuity, (b) the 2027 option cliff, (c) illiquidity vs SPUT, and (d) a suspicion that uranium's AI-demand narrative is over-hyped. The bull calls the discount "free upside"; the bear calls it "the market's fair estimate of the structural haircut."
• Worst capital-allocation risk: the manager is paid a % of the pile, creating a bias to keep the pile big (resist buybacks/wind-downs) even when shrinking would serve shareholders — the classic external-manager misalignment. The buyback is welcome but small; watch whether it's ever sized to actually close the discount or just to look responsive.
• What must hold for today's price: uranium stays ≥$80s and the discount doesn't widen. Break either and you lose money twice (NAV down + discount out). If uranium disappoints 20–30% (→ ~$60/lb), NAV falls ~15–20% and the discount likely widens toward 25% → a plausible ~35–40% drawdown in the shares.
• The single impairing scenario: a durable uranium bear (Kazatomprom + new supply by 2028–30 closes the deficit the bulls insist is permanent) turns YCA into a slowly-bleeding (fees) discount-trap holding a depreciating asset — with no earnings, no dividend, and no self-help beyond a token buyback. Plausibility: moderate — the supply deficit is real today, but "decades of underinvestment" narratives have broken before when price incentivised supply.

---

Fifteen questions for the board/CEO (ordered by information value)

1. The Kazatomprom Framework Agreement expires in 2027 — is renewal under negotiation, on what terms, and if it lapses what specifically differentiates Yellow Cake from SPUT?
2. What explicit discount policy governs the buyback — at what discount, and at what scale, will you repurchase, and would you ever size it to close the discount rather than merely lean against it?
3. Would the board consider a discount-control mechanism, redemption facility, or wind-down/realisation option if the discount persists beyond [X] months above [Y]%?
4. What spot-price index and dating convention do you use to mark NAV, and how do you guard against a stale or favourable mark in a thin market?
5. The 308 Services fee scales with the gross pile, not per-share performance — how does the board ensure the manager is incentivised to shrink the vehicle when that serves shareholders?
6. Under what circumstances, if any, would Yellow Cake sell or lend uranium (a carry/monetisation), versus the pure buy-and-hold mandate?
7. What is your framework for choosing between exercising the Kazatomprom option, buying spot, issuing equity, and buying back stock in any given quarter?
8. How concentrated is custody across Cameco vs Orano, and what are the title/commingling and insurance protections at each converter?
9. What is management and board insider ownership, and how is it structured to align with per-share (not per-pound) value?
10. How do you think about GBP/USD — is the currency mismatch (USD assets, GBP quote) hedged, and if not, why is that the right call for shareholders?
11. What would it take for you to re-start issuance — and do you commit to only issuing at a genuine premium to NAV?
12. How exposed is the Kazatomprom supply channel to routing/logistics risk (Trans-Caspian corridor, sanctions), and what is the contingency?
13. What is your read on the spot-vs-term divergence (~$85 vs ~$91.50) — a temporary dislocation or a structural feature you can arbitrage via the option?
14. If uranium fell to $60/lb and stayed there for two years, what is the plan beyond "hold and buy back"?
15. Is there a scenario in which the board concludes the listed physical-holder structure has outlived its usefulness (e.g., ETFs/SPUT dominate flows) and returns capital?

---